HGF’s life sciences attorneys understand the challenges associated with commercially focused IP management and can advise on the pertinent issues, from invention conception through to patent term extension, to maximise the value of intellectual property.
As one of Europe’s largest groups of specialist life science attorneys, HGF has the wealth of technical and legal expertise to deliver truly global, commercially-focused strategies.
From protecting new research from Europe’s most prestigious universities, to high-profile oppositions for international healthcare companies on market-leading technologies, the team possesses in-depth legal experience. Particular technical expertise within the group covers the fields of food technology, microbiome for therapeutic purposes, cell and gene therapy, bioinformatics, cleantech, AgBio, immunobiology, gene editing technologies, personalised medicine, bioprocessing and anti-infectives.
In addition, our life sciences attorneys work closely with our IP lawyers in relation to life cycle agreements such as MTAs, R&D collaborations, companion diagnostics, IP licensing, clinical trials through to commercial manufacturing and supply, and litigation.
The Court of Appeal has stayed an interim injunction to allow Mylan’s generic to remain on the market in a bid to preserve the status quo, despite recognising that damages …Read article
After months of research, Managing IP has published the IP Stars list for 2022. HGF is delighted to have 16 attorneys from England, Scotland, Ireland, Netherlands and Germany recognised and …Read article
We are delighted to announce that HGF is shortlisted for 11 awards at the upcoming Managing IP EMEA Awards 2022: European European Firm of the Year – Patent Contentious (Patent …Read article
We are excited to mark and celebrate our 3-year partnership with award winning charity In2Science UK. Our partnership has gone from strength to strength, and we are delighted to confirm …Read article
Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …Read article
The UK musician, Ed Sheeran, one of the world’s best selling artists with sales of 26 million albums and 100 million singles worldwide, has successfully defended a claim brought against …Read article
The pilot project for oral proceedings held by videoconference (VICO) in opposition cases has been further extended to 31 December 2022. This is due to ongoing safety concerns about the …Read article
The first meetings of the UPC Administrative, Budget and Advisory Committee took place at the end of February. Following these, the Advisory Committee have begun interviewing judges for the court …Read article